Texting while Sleepwalking
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
and is that our new cdmo btw?
Interesting case study article on Brilacidin
Nice bar chart in the middle of the page. It reminds us just how many other therapeutics are in the clinical stages
https://www.seqens.com/en/what-flow-chemistry-and-biocatalysis-bring-to-synthesize-a-typical-small-molecule-candidate-against-covid-19-epidemic/
Let IPIX name the CDMO if the IV Brilacidin is in the works
They did it in the past. Some have mentioned the company is reluctant to keep quiet when they have good news to release. July 13th he mentioned the manufacturer has a timeline and we are shooting for human trials before end of year, however we still need to submit fda paperwork which can take up to a month to review. Give investors the timeline too as it seems material information.
Previous IPIX PRs naming CDMO:
http://www.ipharminc.com/press-release/2018/7/17/innovation-pharmaceuticals-signs-drug-product-manufacturing-contract-with-corerx-to-formulate-and-package-brilacidin-for-oral-mucositis-in-sachet-form
http://www.ipharminc.com/press-release/2018/4/23/innovation-pharmaceuticals-signs-drug-supply-contract-with-evonik-to-bulk-produce-commercial-grade-brilacidin
doji yesterday. will it be the reversal?
Just so i follow what you are saying
Aspire exercise price .38 for $8 million
The dollar amount IPIX had in the bank prior to July 15 amended Leviston filing?
Shares for the MFO below .20. In this case MFO is? Leviston. This is the first time I am seeing this interpretation. tia
If a financing company receives 15.9 million shares for $6 million cash, how can that financing company stay in business selling under .30? I can see a financing company short the stock above .40 prior to the conversion and make an instant roi.
Today's low works better with this chart. Yesterday's low didnt touch support.
I tried replying yesterday but it looked like you edited the response a few times. i have been there myself
You brought up valid points.
I just kept it simple going off of VEEV and known RBL's:
Colorado State University
Duke University
George Mason University
Rutgers University
Tufts University
Tulane University
University of Alabama
University of Chicago
University of Louisville
University of Missouri
University of Pittsburgh
University of Tennessee
I pretty much just google the RBL and VEEV to see which RBLs had a focus on VEEV. The one that jumps out of course is GMU for a few reasons, the main indicator being the announcement of Narayan stating she is researching Brilacidin and her other announcements that say she is looking for federal funding for covid 19 research.
The quicker updates out of the RBL vs the PHRI to me suggest the RBL has a greater interest in Brilacidin. Did IPIX ever mention the PHRI submitted a federal grant app? We all know IPIX confirmed RBL did.
Then again maybe ipix is .25 cause trump knows about it. Lol
good looking chart
Can we comment on narcissism like others are pointing out how annoying angst is? lmfao. i needed that laugh
Anything is possible. I did email the researcher listed in the June 5 GMU announcement where it talks about Brilacidin. That is the only piece of information I am holding on to my investment here. We all have some time during they day to put our thoughts together. IPIX CEO should issue an investor update and not just release info as they receive it.
Funny story. Years ago i was in another otc stock. A poster had the same name as the IR rep. When he emailed the ceo looking for an update, the poster was sent the PR schedule for the next 3 weeks. IPIX may very well have all the cards but will pick and chose which day of the week to release info at their discretion to keep liquidity/interest up. Fortunately here it seems the ceo is the ir deparment.
The problem is we are all guessing/hypothesizing. This should be coming from IPIX and not investors. Hence the continuing sell off but according to one poster there will be great news today
My comment was a general statement about many pinksheet stock ceos
My fear a few weeks ago was that the ceo talks to maybe 1 or 2 investors. Those investors have long time buddies on the boards they feel they can trust with information. That information indirectly makes it to the board
I think there was credibility to the July 17th meeting; GMU announced the Rapid NSF grants for July
https://www2.gmu.edu/news/587366
I don't see Brilacidin on this list of grants - can anyone find a disclaimer saying some grants have a NDA?
Someone posted this morning they were given the information as to the meeting on the 17th. Why not just PR it or is someone using the phrase "i think" enough to justify it not being credible?
The federal grant was submitted by the RBL the week of JUNE (not july as someone recapped yesterday) 11th. That's 6 weeks. Is that normal in 'warp speed' time not to hear back on a life saving therapeutic.
Question. Double blind trial with placebo group set up. You are a sick patient. You unknowingly are receiving the placebo. The majority of patients receiving the drug are seeing amazing health improvents while the placebo group gets worse, even resulting in death. At what point does the placebo group start to receive the drug?
The easiest one to come up with is the other pinksheet stock leronlimab. They too like to compare themselves to Gilead
There is a spreadsheet with all tbe companies in various stages for covid related pre and clinical trials. The list is quite large. The links have been posted previously by various posters
As for complaining, pinksheet ceos have a certain way of handling business matters. Let the ceo be clear and direct when updating investors cause at this point everyone has had to second guess something the ceo meant. That's what I am used to seeing. Let ipix prove the critical people wrong and I think my comments are taking it easy on the company.
Companies like moderna are tossing the idea around of an EUA to get their vaccine in the public before receiving approval. Out of the scores of covid therapeutics out there right now and not one mention of brilacidin in msm why would we get an eua?
We are not the only company below the msm radar that have statistically significant results
Ipix please prove me wrong
I know that is the goal, but that goal is contigent upon several factors. Ipix needs to win the market's trust back. Get the ind package submitted. It can take up to 4 weeks for an ind package to receive approval. Clinical trial Approval should be the real turning point.
So if there is no news tomorrow will you please own up to it at least.
These are all interesting points that could easily be clarified by the company. I think its been 6 weeks since we heard the grant app was submitted by the rbl. a person has to start asking themselves what's going on with the grant app and ones mknd start to draw its own conclusions.
Btw if no news tomorrow can the other poster with outlandish posts just stop. Its doing more harm then good
isn't that paragraph referring to testing / diagnostics? point of care tests?
Trader vs investor philosophy
the company is riding the covid wave, but the market is not buying it
the company needs to update all investors equally and not the typical pinksheet inclusion of a handful investors who get returned calls or emails from the company to address concerns.
keep making money. good for you
The main saving grace here is to get confirmation that Brilacidin will have it's own trial. It seems all the covid data we are receiving is because Brilacidin is part of larger studies. The RBL seems to be working on a dna nanotechnology delivery platform for VEEV and recently modified their study to include covid19. At this point I assume we paid GMU $35,000 so they would include Brilacidin to be researched and not that GMU specifically requested Brilacidin. This is an assumption, not fact.
In the past IPIX named the CDMO. I mentioned IPIX backtracked on the way the CDMO news first starting coming out (which i know is still up for debate). Another assumption, I am starting to think there is no specific CDMO under contract with IPIX for Covid19, but a just few emails and phone calls were made.
There is nothing more than I would like to see for Brilacidin to succeed. For IPIX to succeed. For the longs to make money. If the goal really is to proceed to human trials, i think the company needs to clear the air with all investors, and not just the long time investors who might have a rapport with the ceo.
The 2 labs we are with are already government funded. If we rely on the IPIX prs we were advised of the RBL's agenda waiting selectivity index and ic50/ic90 values at lower concentration
Ipix needs the iv medication for covid trials
I can't imagine we get special attention without the drug ready. Any WH update on new therapeutics i can't imagine including preclinical drugs.
However the rbl we are with submitted the federal grant app raising our chances of receiving special government attention.
Haven't heard anything out of the phri conducting their own tests
I would assume letting shareholders know ind has been submitted to fda
Apparently statistically significant data only goes so far in an otc stock
There were 3 MTAs
1) RBL; ongoing
2) PHRI; ongoing
3) University; vaccine; study stopped
The vaccine route was pretty much stopped. However using Brilacidin as a prophylactic not a vaccine is in the works
We now have preliminary in vitro data from two separate independent laboratories that, cumulatively, support Brilacidin’s ability to act directly on the novel coronavirus, as a virucidal agent, and prevent viral binding to host cells.
I am looking through the GMU site now
Here is another article posted in April about the $314,000 Army funding
https://science.gmu.edu/news/mason-scientists-dna-nanotech-research-could-target-illnesses-such-coronavirus
Veneziano and Narayanan are seeking funding from the government and industry to study nanotechnology for vaccines for the coronavirus in the same way. “We’re working as fast as we can to develop a vaccine platform that could be applied quickly to other emerging viruses,” Veneziano says.
The IPIX April investor update came out April 20th, 2 days after the article mentioned in that PR about 'inhalation'
April 18
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7165072/
April 20
http://www.ipharminc.com/new-blog/2020/4/20/brilacidin-for-covid-19-updated-overview-available-for-download
There was a special call-out in the April 20th presentation to this article which was eventually published online in June:
https://www.future-science.com/doi/10.2144/btn-2020-0042
The PR said the RBL submitted the federal grant and we are collaborator
http://www.ipharminc.com/press-release/2020/6/17/innovation-pharmaceuticals-brilacidin-inhibits-sars-cov-2-covid-19-by-97-percent-in-a-human-lung-cell-line
Testing results observed to date formed the basis for a federal grant application that was submitted last week by the RBL, in collaboration with the Company, proposing to evaluate Brilacidin’s potential as a pan-coronavirus therapeutic, with possible extension into other viruses.
In the May 19th IPIX PR "Brilacidin Reduces Viral Titer of SARS-CoV-2 (COVID-19) by 75 Percent After Only 1 Hour of Preincubation in In Vitro Study at BSL-3 Facility" the company calls attention to this article
The review article linked below more broadly supports the therapeutic and prophylactic potential of Host Defense Proteins/Antimicrobial Peptides and their mimetics, like Brilacidin, against coronaviruses.
The March 12th IPIX PR connects the dots
Staff scientists at the RBL will evaluate Brilacidin’s potential inhibitory efficacy against SARS-CoV-2 in lung epithelial cell lines, as well as its potential inhibitory effect in viral replication of the alphavirus (with Venezuelan Equine Encephalitis Virus [VEEV] as a prototype) in different cell lines.
That's a pretty interesting coincidence
March 10, 2020
https://volgenau.gmu.edu/news/583841
Veneziano and Narayanan are using DNA nanotechnology to lay the foundation for developing vaccines that could block infection from VEEV.
VEEV has been chosen as a prototype because of the RBL’s focus in this area, possessing in-house necessary assays to assess the antiviral and anti-inflammatory activity of a given compound.
let us know what you find. i am not sure the current ceo has been the ceo of any other pinksheet stock that would show a history of r/s. as for some of your other comments, the website is not maintained. basic stuff such as the linkedin profile goes to the previous company.
Fortunately, or probably more fitting, unfortunately, it is because of Covid 19 that IPIX is on the radar. IPIX wasn't looking to push Brilacidin as an anti covid drug, but it was through database searches and previous clinical data that led institutions to IPIX. That being said, this company was down in the dumps with all the other high flying stocks today that were in similar situations; vxrt, ibio, vbiv, htbx, aim, etc... it's not surprising the site isn't up to date
Just read the march 10th pr - the RBL is doing all the initial legwork. We just happen to own the drug. Independent parties to IPIX are paying for it. That's why I am trying to figure out where the money is coming from. I assume we are part of a grant already indirectly. Now that the testing has shown Brilacidin might just have a role in making people's lives better in a Covid19 world, IPIX is trying to get direct funding now that the RBL and PHRI have done the initial legwork. The RBL even submitted the federal grant(s) and we are collaborator. again, this all points to not relying what you see on the surface such as the website or previous stock history... we are living in a new covid 19 reality
Is brilacidin considered an amp?
Drs. Aarthi Nayayanan and Kylene Kehn-Hall receive U.S. Department of Defense funding
The U.S. Department of Defense awarded $7.82 million to Drs. Aarthi Nayayanan and Kylene Kehn-Hall for genome-wide mapping to study alphavirus proteome interactions and anti microbial peptides as therapeutic strategies for alphavirus infections.
https://science.gmu.edu/research/grants-and-awards
Seems like the GMU researcher is working with DNA nanotechnology platform to solve the cornovavirus. Would Brilacidin be useful? I can pick and choose the data from recent IPIX PR's that could make this sound almost too perfect. Alas, i am not a scientist and not looking to confuse myself or others more then necessary.
https://volgenau.gmu.edu/news/583841
Viral challenges are emerging constantly, and they change constantly, Narayanan says. "The beauty of this technology is it will lend itself to any pathogen we can think of.”
If we look at the July 15th SEC amended filing, Leviston Resources LLC says they own 15,960,000 shares of Common Stock Class A
http://www.ipharminc.com/financials
July 7th the company issues a PR stating: The Company also reports that all preferred shares and warrants previously allotted as part of a financing arrangement have been exercised, establishing a cash balance of approximately $6 Million as of June 30, 2020
http://www.ipharminc.com/press-release
Let's assume IPIX had a $0 cash balance on June 29, 2020 and there is an exact $6 million cash balance now. $6 million / 15,960,000 = .375
I might be totally off base (won't be the first time)
What information do we have the suggests the price in which Leviston Resources LLC owns IPIX stock is less than .375?
Or better yet, today's low I believe was .28, so let's not be so generous. What would suggest Leviston is able to make money on their deal by selling at .30 or below?
Please someone clarify in fact, not opinion, how it makes sense for someone agreeing to pay $6 million for approx 16 million shares benefits by selling less that .38 per share
I have watched many secondaries and atms done recently where the stock goes down below the offering price because of uncertainty. Ultimately the stock price shoots way up over the offering price. What was the offering price by the way? Are we going to talk science or conspiracy theory?
well knowing how otc stocks work, there is a schedule of prs already in the works. the strategy here seems to up the prs from 1 to 2 per week to keep liquidity going. have to be patient and not watch tic by tic unless daytrading. i still think anticipation will come into ipix's favor... even overcoming the crowd selling on friday's for beer money
Thanks. She is a trooper and pulled through. For ipix and many other drug stocks, covid development is driving most of them in today's market. Can't wait to see the future for k